Pfizer stock is trading in a range where recent returns have been weak over three years, yet the broader valuation checks ...
Pfizer (PFE) is back in focus for investors as its latest reported figures offer a snapshot of how the US$143.7b pharmaceutical group is positioned, with value metrics and recent returns drawing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results